Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731210 | 1.00 | GALR3 (0.39) | GALR3NR2F2ADKADORA3ADORA2A | |
| SCHEMBL16727958 | 0.84 | ADORA1 (0.40) | ADKADORA3ADORA2ALGALS9LGALS1 | |
| SCHEMBL21073965 | 0.84 | ADORA1 (0.40) | ADKADORA3ADORA2ALGALS9LGALS1 | |
| SCHEMBL25495898 | 0.84 | ADORA1 (0.40) | ADKADORA3ADORA2ALGALS9LGALS1 | |
| SCHEMBL20243833 | 0.78 | ABL1 (0.35) | ABL1RIN1 | |
| SCHEMBL18490384 | 0.77 | GALR3 (0.41) | GALR3NR2F2ADKADORA3POLB | |
| SCHEMBL25495889 | 0.76 | LGALS9 (0.35) | ADORA3ADORA2ALGALS9LGALS1LGALS3 | |
| SCHEMBL17106668 | 0.76 | HIF1A (0.39) | ADKADORA3ADORA2APOLB | |
| SCHEMBL16731212 | 0.76 | ADORA2A (0.38) | ADKADORA3ADORA2A | |
| SCHEMBL25399504 | 0.74 | TMPRSS2 (0.44) | GALR3NR2F2ADKADORA3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | GALR3 565/4885NR2F2 915/4885ADK 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.